Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Anatomic Pathology Reference Lab, Seegene Medical Foundation, Seoul, Republic of Korea.
Cancer Genomics Proteomics. 2022 Mar-Apr;19(2):259-269. doi: 10.21873/cgp.20318.
BACKGROUND/AIM: Transient receptor potential vanilloid 6 (TRPV6), an endothelial Ca-selective entry channel, is expressed in various cancer types, and a selective TRPV6 inhibitor is currently being investigated in a clinical trial. However, TRPV6 expression in hepatocellular carcinoma (HCC) has not been reported.
We evaluated TRPV6 expression in 219 cases of HCC and analyzed its association with clinicopathological parameters and prognostic significance. TRPV6 mRNA expression was compared between HCC and non-tumor liver tissues using various public datasets, and its prognostic effect was examined in The Cancer Genome Atlas (TCGA) cohort.
Low TRPV6 expression was found in 37.4% of patients, which was significantly associated with adverse histologic features, and patients with low TRPV6 expression had shorter recurrence-free and disease-free survival. TRPV6 mRNA expression was consistently lower in HCC compared to non-tumor liver samples in public datasets, at the whole tissue level as well as single-cell level. Patients with low TRPV6 expression in the TCGA cohort had shorter progression-free survival.
TRPV6 expression is down-regulated in HCCs and associated with a poor prognosis. TRPV6 may be a prognostic biomarker in HCC.
背景/目的：瞬时受体电位香草素 6（TRPV6）是一种内皮细胞钙离子选择性通道，在多种癌症类型中表达，目前正在临床试验中研究其选择性抑制剂。然而，TRPV6 在肝细胞癌（HCC）中的表达尚未见报道。
我们评估了 219 例 HCC 中 TRPV6 的表达，并分析了其与临床病理参数的关系及其预后意义。使用各种公共数据集比较 HCC 和非肿瘤肝组织中 TRPV6 mRNA 的表达，并在癌症基因组图谱（TCGA）队列中检查其预后效果。
37.4%的患者 TRPV6 表达较低，与不良组织学特征显著相关，TRPV6 低表达的患者无复发生存和无病生存时间更短。在公共数据集以及整个组织和单细胞水平上，与非肿瘤肝样本相比，HCC 中 TRPV6 mRNA 的表达始终较低。TCGA 队列中 TRPV6 低表达的患者无进展生存期更短。
TRPV6 在 HCC 中表达下调，与预后不良相关。TRPV6 可能是 HCC 的预后生物标志物。
